Literature DB >> 23504380

First-degree relatives of patients with rheumatoid arthritis exhibit high prevalence of joint symptoms.

Irene Smolik1, David B Robinson, Charles N Bernstein, Hani S El-Gabalawy.   

Abstract

OBJECTIVE: The preclinical period of rheumatoid arthritis (RA) is characterized by the presence of autoantibodies such as anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). Little is known about the joint symptom profile preceding onset of RA, and whether symptoms are associated with RA autoantibodies. Because first-degree relatives (FDR) of North American Native (NAN) RA probands exhibit multiple risk factors for development of future RA, we investigated the prevalence of joint symptoms in this high-risk population.
METHODS: We studied 306 FDR of NAN patients with RA, 323 NAN controls (NC), and 293 white controls (WC) having no family history of autoimmune diseases. Study subjects completed a questionnaire that asked whether they had pain, swelling, or morning stiffness in their hand joints, or in other joints. Serum samples were gathered at the same time and tested for the presence of ACPA, RF, and high-sensitivity C-reactive protein levels.
RESULTS: In all cases, FDR were significantly more likely to report experiencing joint symptoms compared to the 2 control groups. FDR also exhibited a significantly higher prevalence of RA autoantibodies than the control groups. There were modest trends for joint symptoms to associate with RA autoantibodies, and individuals who were both ACPA-positive and RF-positive had the highest prevalence of joint symptoms.
CONCLUSION: FDR of NAN patients with RA have a higher prevalence of joint symptoms compared to individuals with no family history of autoimmune disease. This finding is only partially explained by a high prevalence of RA autoantibodies in the FDR.

Entities:  

Keywords:  ANTICITRULLINATED PROTEIN ANTIBODIES; FIRST-DEGREE RELATIVE; JOINT SYMPTOMS; NORTH AMERICAN NATIVE; PREVALENCE; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2013        PMID: 23504380     DOI: 10.3899/jrheum.121016

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study.

Authors:  Rosana Quintana; Mario Goñi; Nora Mathern; Marisa Jorfen; Silvana Conti; Romina Nieto; Alvaro Sanabria; Cristina Prigione; Adriana M R Silvestre; Vanina García; Guillermo Pons-Estel; Ricard Cervera; Conrado García; Ingris Peláez-Ballestas; Graciela S Alarcón; Bernardo A Pons-Estel
Journal:  Clin Rheumatol       Date:  2018-04-19       Impact factor: 2.980

Review 2.  Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE.

Authors:  Kevin D Deane; Hani El-Gabalawy
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

Review 3.  The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA.

Authors:  Annie Yarwood; Tom W J Huizinga; Jane Worthington
Journal:  Rheumatology (Oxford)       Date:  2014-09-18       Impact factor: 7.580

4.  Prevalence of musculoskeletal disorders and rheumatic diseases in the indigenous Qom population of Rosario, Argentina.

Authors:  Rosana Quintana; Adriana M R Silvestre; Mario Goñi; Vanina García; Nora Mathern; Marisa Jorfen; Julio Miljevic; Daniel Dhair; Matias Laithe; Silvana Conti; Fadua Midauar; Maria Celeste Martin; Maria Cecilia Barrios; Romina Nieto; Cristina Prigione; Alvaro Sanabria; Viviana Gervasoni; Emilio Grabbe; Romina Gontero; Ingris Peláez-Ballestas; Bernardo A Pons-Estel
Journal:  Clin Rheumatol       Date:  2016-02-06       Impact factor: 2.980

5.  Characterization of Autoantigens Targeted by Anti-Citrullinated Protein Antibodies In Vivo: Prominent Role for Epitopes Derived from Histone 4 Proteins.

Authors:  Xiaobo Meng; Peyman Ezzati; Irene Smolik; Charles N Bernstein; Carol Ann Hitchon; Hani S El-Gabalawy
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

6.  Prevalence and Incidence of Upper Respiratory Tract Infection Events Are Elevated Prior to the Development of Rheumatoid Arthritis in First-Degree Relatives.

Authors:  Marina I Arleevskaya; Shafigullina Albina; Regina V Larionova; Aida G Gabdoulkhakova; Julie Lemerle; Yves Renaudineau
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

7.  N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis.

Authors:  Lise Hafkenscheid; Emma de Moel; Irene Smolik; Stacey Tanner; Xiaobo Meng; Bas C Jansen; Albert Bondt; Manfred Wuhrer; Tom W J Huizinga; Rene E M Toes; Hani El-Gabalawy; Hans U Scherer
Journal:  Arthritis Rheumatol       Date:  2019-09-02       Impact factor: 10.995

8.  Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis.

Authors:  Laure Brulhart; Deshiré Alpízar-Rodríguez; Michael S Nissen; Pascal Zufferey; Ileana Ciubotariu; Gregory Fleury; Ilias Lazarou; Cem Gabay; Axel Finckh
Journal:  RMD Open       Date:  2019-08-23

9.  A bioavailable form of curcumin, in combination with vitamin-D- and omega-3-enriched diet, modifies disease onset and outcomes in a murine model of collagen-induced arthritis.

Authors:  Mahadevappa Hemshekhar; Vidyanand Anaparti; Hani El-Gabalawy; Neeloffer Mookherjee
Journal:  Arthritis Res Ther       Date:  2021-01-25       Impact factor: 5.156

10.  Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project.

Authors:  Marian H van Beers-Tas; Marieke M Ter Wee; Lilian H van Tuyl; Bertha Maat; Wijnanda Hoogland; Aase H Hensvold; Anca I Catrina; Erika Mosor; Tanja A Stamm; Axel Finckh; Delphine S Courvoisier; Andrew Filer; Ilfita Sahbudin; Rebecca J Stack; Karim Raza; Dirkjan van Schaardenburg
Journal:  RMD Open       Date:  2018-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.